Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.   7 September 2023
Biotechnology
Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.   7 September 2023
Big Pharma
Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos.   29 August 2023
Americas
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.   17 August 2023
Big Pharma
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.   15 August 2023
Big Pharma
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.   15 August 2023
Big Pharma
A reticent patent office and complex legal picture make getting IP protection of treatments based on the lucrative plant tricky, explain Priscila Kashiwabara and Luan Scalzitti of Kasznar Leonardos.   3 August 2023
Asia
Amid worldwide interest, India could position itself as a global hub for a desperately needed technology, say Kavita Arora and Shaivya Dhawan of K&S Partners.   1 August 2023
Americas
Amid criticism against restrictive covenants such as non-competes, what can life sciences firms do to keep their trade secrets safe and defend against unfair competition, ask David Pardue, Patti Bartis, and Sarah Hutchins of Parker Poe.   25 July 2023
Generics
Generic drug makers are watching two cases that will determine whether pharmaceutical firms can deduct—rather than capitalise—legal fees for defending against patent infringement suits, say Carina Federico and Anne Li of Crowell & Moring.   18 July 2023